Indication

Treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide

Medicine details

Medicine name:
voxelotor (Oxbryta) SMC2626
SMC ID:
SMC2626
Pharmaceutical company
Pfizer Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC